Erste Group Bank Reduces Earnings Estimates for Novartis

Novartis AG (NYSE:NVS) – Stock analysts at Erste Group Bank lowered their FY2027 earnings estimates for shares of Novartis in a report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $9.80 per share for the year, down from their previous forecast of $9.82. The consensus estimate for Novartis’ current full-year earnings is $8.84 per share.

A number of other research analysts also recently weighed in on NVS. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Novartis has an average rating of “Hold” and an average price target of $141.20.

Novartis Price Performance

NVS stock opened at $152.22 on Tuesday. The stock has a market capitalization of $290.46 billion, a PE ratio of 22.96, a price-to-earnings-growth ratio of 2.64 and a beta of 0.45. The company’s 50-day moving average is $155.14 and its 200-day moving average is $153.72. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. Novartis has a 1 year low of $121.57 and a 1 year high of $170.46.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%.

Hedge Funds Weigh In On Novartis

Large investors have recently added to or reduced their stakes in the business. Archer Investment Corp increased its holdings in Novartis by 93.0% during the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after purchasing an additional 80 shares in the last quarter. Highland Investment Advisors LLC bought a new position in shares of Novartis in the second quarter valued at approximately $25,000. Evolution Wealth Management Inc. lifted its holdings in shares of Novartis by 552.0% in the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after purchasing an additional 138 shares in the last quarter. Atlatl Advisers LLC purchased a new position in shares of Novartis during the second quarter valued at approximately $26,000. Finally, CrossGen Wealth LLC purchased a new position in shares of Novartis during the fourth quarter valued at approximately $28,000. Institutional investors own 13.12% of the company’s stock.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.